Belite Bio to Host Webcast on August 11, 2025, to Discuss Second Quarter 2025 Financial Results
Belite Bio (NASDAQ: BLTE), a clinical-stage drug development company specializing in novel therapeutics for degenerative retinal diseases, has scheduled a webcast for Monday, August 11, 2025, at 4:30 p.m. Eastern Time. During this event, the company will discuss its Q2 2025 financial results and provide a business update for the quarter ended June 30, 2025.
The webcast will be accessible through the company's investor relations website, and a replay will remain available for approximately 90 days following the event.
Belite Bio (NASDAQ: BLTE), un'azienda in fase clinica specializzata nello sviluppo di terapie innovative per le malattie degenerative della retina, ha programmato una webcast per lunedì 11 agosto 2025, alle 16:30 ora orientale. Durante l'evento, l'azienda discuterà i suoi risultati finanziari del secondo trimestre 2025 e fornirà un aggiornamento sulle attività relative al trimestre terminato il 30 giugno 2025.
La webcast sarà accessibile tramite il sito web delle relazioni con gli investitori dell'azienda e la registrazione rimarrà disponibile per circa 90 giorni dopo l'evento.
Belite Bio (NASDAQ: BLTE), una empresa en etapa clínica especializada en el desarrollo de terapias novedosas para enfermedades degenerativas de la retina, ha programado una transmisión en línea para el lunes 11 de agosto de 2025, a las 4:30 p.m. hora del Este. Durante este evento, la compañía presentará sus resultados financieros del segundo trimestre de 2025 y proporcionará una actualización comercial correspondiente al trimestre finalizado el 30 de junio de 2025.
La transmisión estará disponible a través del sitio web de relaciones con inversionistas de la empresa, y la repetición permanecerá accesible aproximadamente 90 días después del evento.
Belite Bio (NASDAQ: BLTE)는 퇴행성 망막 질환을 위한 혁신 치료제 개발에 특화된 임상 단계의 제약 회사로, 2025년 8월 11일 월요일 오후 4시 30분(동부 표준시)에 웹캐스트를 예정하고 있습니다. 이 행사에서 회사는 2025년 2분기 재무 결과를 발표하고 2025년 6월 30일로 종료된 분기의 사업 현황을 업데이트할 예정입니다.
웹캐스트는 회사의 투자자 관계 웹사이트를 통해 접속할 수 있으며, 행사가 끝난 후 약 90일간 다시보기 서비스를 제공합니다.
Belite Bio (NASDAQ : BLTE), une société en phase clinique spécialisée dans le développement de traitements innovants pour les maladies dégénératives de la rétine, a programmé une webdiffusion pour le lundi 11 août 2025 à 16h30, heure de l’Est. Lors de cet événement, la société présentera ses résultats financiers du deuxième trimestre 2025 et fournira une mise à jour commerciale pour le trimestre clos le 30 juin 2025.
La webdiffusion sera accessible via le site des relations investisseurs de la société, et un replay restera disponible pendant environ 90 jours après l'événement.
Belite Bio (NASDAQ: BLTE), ein klinisch tätiges Unternehmen, das sich auf neuartige Therapeutika für degenerative Netzhauterkrankungen spezialisiert hat, hat eine Webcast für Montag, den 11. August 2025, um 16:30 Uhr Eastern Time angesetzt. Während dieser Veranstaltung wird das Unternehmen seine Finanzergebnisse für das zweite Quartal 2025 vorstellen und ein Geschäftsupdate für das am 30. Juni 2025 endende Quartal geben.
Der Webcast ist über die Investor-Relations-Website des Unternehmens zugänglich, und eine Aufzeichnung wird etwa 90 Tage nach der Veranstaltung verfügbar bleiben.
- None.
- None.
SAN DIEGO, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it will host a webcast on Monday, August 11, 2025, at 4:30 p.m. Eastern Time to discuss the Company’s financial results and provide a business update for the second quarter ended June 30, 2025.
Webcast Information
Date: Monday, August 11, 2025
Time: 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time)
Webcast Link: https://events.q4inc.com/attendee/127464226
Webcast Link Instructions
You can join the live webcast by visiting the link above or the “Presentations & Events” section of the Company’s Investor Relations website at https://investors.belitebio.com/presentations-events/events. A replay will be available for approximately 90 days after the event.
About Belite Bio
Belite Bio is a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, such as Stargardt disease type 1 (STGD1) and Geographic Atrophy (GA) in advanced dry age-related macular degeneration (AMD), in addition to specific metabolic diseases. Belite’s lead candidate, Tinlarebant, an oral therapy intended to reduce the accumulation of toxins in the eye, is currently being evaluated in a Phase 3 study (DRAGON) and a Phase 2/3 study (DRAGON II) in adolescent STGD1 subjects and a Phase 3 study (PHOENIX) in subjects with GA. For more information, follow us on X, Instagram, LinkedIn, Facebook or visit us at www.belitebio.com.
Media and Investor Relations Contact:
Jennifer Wu
ir@belitebio.com
Julie Fallon
belite@argotpartners.com
FAQ
When is Belite Bio (BLTE) hosting its Q2 2025 earnings webcast?
How can investors access Belite Bio's Q2 2025 earnings webcast?
How long will the replay of Belite Bio's Q2 2025 earnings webcast be available?
What is Belite Bio's main business focus?
